Annual CFF
$10.57 M
+$8.72 M+470.73%
01 June 2024
Summary:
Kintara Therapeutics annual cash flow from financing activities is currently $10.57 million, with the most recent change of +$8.72 million (+470.73%) on 01 June 2024. During the last 3 years, it has fallen by -$15.47 million (-59.41%).KTRA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$7.99 M-100.00%
01 June 2024
Summary:
Kintara Therapeutics quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$7.99 million (-100.00%) on 01 June 2024. Over the past year, it has increased by +$2000.00 (+100.00%).KTRA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$10.57 M
+$2000.00+0.02%
01 June 2024
Summary:
Kintara Therapeutics TTM cash flow from financing activities is currently $10.57 million, with the most recent change of +$2000.00 (+0.02%) on 01 June 2024. Over the past year, it has increased by +$10.63 million (+18975.00%).KTRA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KTRA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +470.7% | +100.0% | +10000.0% |
| 3 y3 years | -59.4% | -100.0% | -36.2% |
| 5 y5 years | +159.4% | -100.0% | -1.1% |
KTRA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -59.4% | -100.0% | -60.2% |
Kintara Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | $10.57 M(+470.7%) | $0.00(-100.0%) | $10.57 M(+0.0%) |
| Mar 2024 | - | $7.99 M(+209.9%) | $10.57 M(+310.7%) |
| Dec 2023 | - | $2.58 M(<-9900.0%) | $2.57 M(-4694.6%) |
| Sept 2023 | - | -$2000.00(0.0%) | -$56.00 K(-103.0%) |
| June 2023 | $1.85 M(-91.4%) | -$2000.00(0.0%) | $1.85 M(-81.1%) |
| Mar 2023 | - | -$2000.00(-96.0%) | $9.79 M(0.0%) |
| Dec 2022 | - | -$50.00 K(-102.6%) | $9.79 M(+1.3%) |
| Sept 2022 | - | $1.91 M(-76.0%) | $9.67 M(-55.3%) |
| June 2022 | $21.64 M(-16.9%) | $7.93 M(<-9900.0%) | $21.64 M(+63.8%) |
| Mar 2022 | - | -$2000.00(-98.8%) | $13.21 M(-19.5%) |
| Dec 2021 | - | -$171.00 K(-101.2%) | $16.41 M(-0.9%) |
| Sept 2021 | - | $13.88 M(-2920.1%) | $16.57 M(-36.4%) |
| June 2021 | $26.04 M(+294.5%) | -$492.00 K(-115.4%) | $26.04 M(-1.8%) |
| Mar 2021 | - | $3.20 M(<-9900.0%) | $26.53 M(+13.7%) |
| Dec 2020 | - | -$16.00 K(-100.1%) | $23.33 M(-0.1%) |
| Sept 2020 | - | $23.35 M(<-9900.0%) | $23.34 M(+253.7%) |
| June 2020 | $6.60 M(+62.0%) | -$3000.00(+50.0%) | $6.60 M(-33.9%) |
| Mar 2020 | - | -$2000.00(+100.0%) | $9.98 M(+0.8%) |
| Dec 2019 | - | -$1000.00(-100.0%) | $9.90 M(-7.3%) |
| Sept 2019 | - | $6.61 M(+95.5%) | $10.68 M(+162.2%) |
| June 2019 | $4.07 M(-56.0%) | $3.38 M(-4034.0%) | $4.07 M(+488.1%) |
| Mar 2019 | - | -$85.90 K(-111.0%) | $692.80 K(-36.4%) |
| Dec 2018 | - | $782.90 K(<-9900.0%) | $1.09 M(+258.1%) |
| Sept 2018 | - | -$2100.00(0.0%) | $304.10 K(-96.7%) |
| June 2018 | $9.25 M(+9.2%) | -$2100.00(-100.7%) | $9.25 M(-46.2%) |
| Mar 2018 | - | $310.40 K(<-9900.0%) | $17.21 M(+0.7%) |
| Dec 2017 | - | -$2100.00(-100.0%) | $17.09 M(-0.4%) |
| Sept 2017 | - | $8.94 M(+12.4%) | $17.16 M(+102.6%) |
| June 2017 | $8.47 M | $7.96 M(+4076.2%) | $8.47 M(+16.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | $190.50 K(+181.4%) | $7.29 M(+3.6%) |
| Dec 2016 | - | $67.70 K(-73.4%) | $7.03 M(-4.6%) |
| Sept 2016 | - | $254.90 K(-96.2%) | $7.37 M(-23.0%) |
| June 2016 | $9.57 M(+1028.3%) | $6.77 M(<-9900.0%) | $9.57 M(+307.3%) |
| Mar 2016 | - | -$62.70 K(-115.6%) | $2.35 M(-3.7%) |
| Dec 2015 | - | $403.10 K(-83.6%) | $2.44 M(-12.0%) |
| Sept 2015 | - | $2.45 M(-652.6%) | $2.77 M(+226.9%) |
| June 2015 | $847.80 K(-65.8%) | -$443.60 K(-1724.9%) | $847.80 K(-34.4%) |
| Mar 2015 | - | $27.30 K(-96.3%) | $1.29 M(-13.1%) |
| Dec 2014 | - | $736.50 K(+39.6%) | $1.49 M(+98.3%) |
| Sept 2014 | - | $527.60 K(+137.9%) | $749.40 K(+237.9%) |
| June 2014 | $2.48 M(-74.3%) | - | - |
| Mar 2014 | - | $221.80 K(>+9900.0%) | $221.80 K(-97.7%) |
| Dec 2013 | $9.64 M(>+9900.0%) | $0.00(0.0%) | $9.64 M(-0.1%) |
| Sept 2013 | - | $0.00(0.0%) | $9.64 M(-0.0%) |
| June 2013 | - | $0.00(-100.0%) | $9.65 M(0.0%) |
| Mar 2013 | - | $9.64 M(>+9900.0%) | $9.65 M(>+9900.0%) |
| Dec 2012 | - | $5000.00(+66.7%) | $13.10 K(+24.8%) |
| Sept 2012 | - | $3000.00(>+9900.0%) | $10.50 K(+40.0%) |
| June 2012 | - | $0.00(-100.0%) | $7500.00(0.0%) |
| June 2012 | $7500.00(>+9900.0%) | - | - |
| Mar 2012 | - | $5100.00(+112.5%) | $7500.00(+212.5%) |
| Dec 2011 | - | $2400.00(>+9900.0%) | $2400.00(>+9900.0%) |
| Sept 2011 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2011 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2011 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2010 | - | $0.00 | $0.00 |
| June 2010 | $49.50 K | - | - |
FAQ
- What is Kintara Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Kintara Therapeutics?
- What is Kintara Therapeutics annual CFF year-on-year change?
- What is Kintara Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Kintara Therapeutics?
- What is Kintara Therapeutics quarterly CFF year-on-year change?
- What is Kintara Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Kintara Therapeutics?
- What is Kintara Therapeutics TTM CFF year-on-year change?
What is Kintara Therapeutics annual cash flow from financing activities?
The current annual CFF of KTRA is $10.57 M
What is the all time high annual CFF for Kintara Therapeutics?
Kintara Therapeutics all-time high annual cash flow from financing activities is $26.04 M
What is Kintara Therapeutics annual CFF year-on-year change?
Over the past year, KTRA annual cash flow from financing activities has changed by +$8.72 M (+470.73%)
What is Kintara Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of KTRA is $0.00
What is the all time high quarterly CFF for Kintara Therapeutics?
Kintara Therapeutics all-time high quarterly cash flow from financing activities is $23.35 M
What is Kintara Therapeutics quarterly CFF year-on-year change?
Over the past year, KTRA quarterly cash flow from financing activities has changed by +$2000.00 (+100.00%)
What is Kintara Therapeutics TTM cash flow from financing activities?
The current TTM CFF of KTRA is $10.57 M
What is the all time high TTM CFF for Kintara Therapeutics?
Kintara Therapeutics all-time high TTM cash flow from financing activities is $26.53 M
What is Kintara Therapeutics TTM CFF year-on-year change?
Over the past year, KTRA TTM cash flow from financing activities has changed by +$10.63 M (+18975.00%)